The current data come from the institutional database and contains confidential patient information. Patients did not approve distribution of their information to the public. Our Institutional Review Board (Wonju Severance Christian Hospital) restricts data distribution for ethical reasons and these restrictions are in line with the approved consent procedure. All data are available upon request. Interested researchers may submit requests for data to the corresponding author.

Introduction {#sec005}
============

Curative surgical resection is the primary treatment modality for colorectal cancer. After resection, adjuvant chemotherapy is performed to reduce the risk of metastasis and recurrence \[[@pone.0138720.ref001]\]. Although quantifying the oncologic benefits of adjuvant chemotherapy is difficult, chemotherapy with fluorouracil and folinic acid improves survival by 3.6% in patients with stage II colorectal cancer \[[@pone.0138720.ref002]\]. According to a meta-analysis by Dube *et al*.\[[@pone.0138720.ref003]\], adjuvant chemotherapy with fluorouracil improved survival by 5% for patients with Dukes C colon cancer and adjuvant chemoradiation therapy increased survival by 9% for patients with Dukes B and C rectal cancer. In 2011, only 64% of patients with stage III colon cancer received adjuvant chemotherapy in the United States \[[@pone.0138720.ref004]\]. Use of chemotherapy is associated with age, race, underlying disease, marital and economic status, and occurrence of postoperative complications \[[@pone.0138720.ref005]\].

The impact of delayed chemotherapy on survival is controversial because of the paucity of high-level evidence. Factors associated with chemotherapy delay are age, race, postoperative recovery, underlying disease, histologic grade, and marital status \[[@pone.0138720.ref006]\].

Although current National Comprehensive Cancer Network (NCCN) guidelines recommend adjuvant chemotherapy for people with stage II and III colorectal cancer after surgery \[[@pone.0138720.ref007], [@pone.0138720.ref008]\], no guidelines have been established for the time to chemotherapy initiation. Most clinical trials favor initiation of adjuvant chemotherapy for colon cancer within 6 to 8 weeks after surgery \[[@pone.0138720.ref009], [@pone.0138720.ref010]\]. Thus, a randomized trial to evaluate the impact of delayed chemotherapy on patient survival would be unethical.

To date, the reasons for use and delay of adjuvant chemotherapy have not been extensively studied and the association between chemotherapy delay and oncologic outcomes remains unclear. This study aimed to evaluate factors affecting the use and delay ≥8 weeks of chemotherapy after colorectal cancer surgery and the impact of chemotherapy use and delay on oncologic outcomes.

Methods {#sec006}
=======

Patients {#sec007}
--------

This retrospective cohort study was performed at a tertiary referral center following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines\[[@pone.0138720.ref011]\]. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki and were approved by the Institutional Review Board of Wonju Severance Christian Hospital (YWMR-14-5-099). All participants provided their written informed consent to participate in this study and the ethics committee approved this consent procedure. Informed consent was obtained from all patients before surgery. Between 2005 and 2012, 750 consecutive patients undergoing major resection for stage II and III colorectal cancer were enrolled. Eligibility criteria were histologically confirmed colorectal cancer and major colorectal resection with curative intent. Patients with stage I and IV disease and those undergoing R2 resection for macroscopic residual disease or nonresectional procedures for colorectal cancer were excluded.

Study endpoints {#sec008}
---------------

The primary endpoint was identifying factors affecting use and delay ≥8 weeks of adjuvant chemotherapy after colorectal cancer surgery. The secondary endpoint was the impact of use and delay of chemotherapy ≥8 weeks on oncologic outcomes.

Preoperative chemoradiation therapy {#sec009}
-----------------------------------

Patients with clinical stage T3 or T4 and/or node-positive rectal cancer underwent preoperative chemoradiation therapy. A long course schedule was used and total radiation dose was 50.4 Gy. Radiation was delivered to the entire pelvis (45 Gy in 25 fractions) with a boost to the primary tumor (5.4 Gy in 3 fractions) over 5 weeks. Intravenous chemotherapy (425 mg/m^2^ 5-fluorouracil and 20 mg/m^2^ leucovorin) was administered during weeks 1 and 5 of radiation therapy.

Surgery, adjuvant therapy, and follow-up {#sec010}
----------------------------------------

After standardized preoperative preparations, standard surgical procedures were performed. Complete mesocolic excision for colon cancer and total mesorectal excision for rectal cancer were performed using standard surgical procedures.

After recovery from surgery, all patients with stage II and III disease were recommended to receive chemotherapy according to NCCN guidelines. All cases were discussed at weekly multidisciplinary team meetings. Oxaliplatin or irinotecan-containing regimens were considered for stage II patients with high-risk features (tumors that were T4 or histological grade 3 or 4; peritumoral lymphovascular involvement; bowel obstruction; T3 lesions with localized perforation; positive resection margin; or perineural invasion). Chemotherapy regimens included fluoropyrimidine (fluorouracil with folinic acid and capecitabine) alone or in combination with oxaliplatin (FOLFOX)/irinotecan (FOLFIRI).

Adjuvant radiation was used for patients with stage II and III rectal cancer. Adjuvant radiation therapy was performed as follows. Fluorouracil-based chemotherapy consisted of 425 mg/m^2^ of 5-fluorouracil and 20 mg/m^2^ of leucovorin for 5 days every 28 days for six cycles. Radiation therapy was performed after the second round of chemotherapy and consisted of 50.4 to 54 Gy delivered in 28 to 30 fractions.

All surgical patients were registered in a dedicated colorectal database and followed at 3- or 6-month intervals for the first 5 years and then yearly thereafter.

Outcome measures {#sec011}
----------------

Time to chemotherapy was defined as the duration from surgery to initiation of adjuvant chemotherapy. Chemotherapy delay was defined using 8 weeks as the cutoff. Postoperative complications were defined as events that required additional treatment within 30 days of surgery, based on the Clavien-Dindo classification. Conversion to open surgery was defined as completion of planned surgical procedures using a conventional laparotomy incision. Treatment-related variables such as intensive care unit (ICU) care or blood transfusions were included in analysis if they were required within 48 hours after primary surgery. The 48-hour limit sought to assess intraoperative patient burdens rather than postoperative complications. We assumed that ICU admission or transfusion within 48 hours indicated immediate surgical stress.

Statistical analysis {#sec012}
--------------------

All statistical analyses used MedCalc Statistical Software version 15.2.2 (MedCalc Software bvba, Ostend, Belgium) and IBM SPSS Statistics for Windows, version 21.0 (IBM, Armonk, NY, USA). Categorical variables were described by frequencies and percentages and compared using chi-square test or Fisher\'s exact test as appropriate. Continuous variables were described as mean and standard deviation and analyzed by Student's *t*-test. Factors associated with use and delay of chemotherapy were identified by logistic regression analysis. Survival analysis was by the Kaplan-Meier method with log rank tests and the Cox proportional hazard model. A *p*-value \<0.05 was considered statistically significant.

Results {#sec013}
=======

Details of adjuvant chemotherapy {#sec014}
--------------------------------

Among 750 patients with stage II (n = 318) or III (n = 432) disease, adjuvant chemotherapy was performed in 597 (79.6%). Among 597 patients with adjuvant chemotherapy, 31 (5.2%) received chemotherapy 8 weeks or more after surgery. Detailed chemotherapy data are presented in **[Table 1](#pone.0138720.t001){ref-type="table"}**.

10.1371/journal.pone.0138720.t001

###### Adjuvant chemotherapy.

![](pone.0138720.t001){#pone.0138720.t001g}

                                               TNM stage                                    
  ---------------------- --------------------- ------------------ ------------ ------------ ---------
  Chemotherapy use       (-) (n = 153)         83 (26.1)          70 (16.2)    0.001        
                         (+) (n = 597)         235 (73.9)         362 (83.8)                
  Time to chemotherapy   \<8 weeks (n = 566)   Fluoropyrimidine   182 (82.4)   187 (54.2)   \<0.001
                                               Oxaliplatin        38 (17.2)    149 (43.2)   
                                               Irinotecan         1 (0.5)      9 (2.6)      
                         ≥8 weeks (n = 31)     Fluoropyrimidine   11 (78.6)    15 (88.2)    0.717
                                               Oxaliplatin        1 (7.1)      1 (5.9)      
                                               Irinotecan         2 (14.3)     1 (5.9)      

Factors associated with no use of adjuvant chemotherapy {#sec015}
-------------------------------------------------------

Based on multivariate analysis, factors associated with not receiving chemotherapy were age ≥80 years (hazard ratio \[HR\] = 5.2), American Society of Anesthesiologists (ASA) score ≥3 (HR = 1.9), underlying cerebrovascular disease (HR = 1.7), stage II disease (HR = 2.0), presence of postoperative complications (HR = 2.2) and ICU admission (HR = 2.4). The use of preoperative chemoradiation for rectal cancer increased the use of adjuvant chemotherapy (11.4% vs. 4.6%, p = 0.012). However, in multivariate analysis, this was not an independent factor for the use of chemotherapy (**[Table 2](#pone.0138720.t002){ref-type="table"}**).

10.1371/journal.pone.0138720.t002

###### Factors associated with not receiving adjuvant chemotherapy (n = 750).

![](pone.0138720.t002){#pone.0138720.t002g}

                                                          Univariate analysis   Multivariate analysis                                     
  --------------------------------- --------------------- --------------------- ----------------------- ---------------- ---------------- ---------
  Age (years)                       \<80                  97 (63.4)             549 (92)                \<0.001          1                \<0.001
                                    ≥80                   56 (36.6)             48 (8)                                   5.2 (3.2--8.4)   
  Age subgroups                     ≤70                   39 (9.9)              356 (90.1)              \<0.001          NA               
                                    71--75                34 (19.8)             138 (80.2)                                                
                                    76--80                35 (33.3)             70 (66.7)                                                 
                                    81--85                27 (50.9)             26 (49.1)                                                 
                                    ≥86                   18 (72)               7 (28)                                                    
  Sex                               Male                  93 (60.8)             382 (64)                0.463            NA               
                                    Female                60 (39.2)             215 (36)                                                  
  BMI                               ≥30 kg/m^2^           9 (5.9)               18 (3)                  0.089            NA               
  ASA score                         3,4                   48 (31.4)             81 (13.6)               \<0.001          1.9 (1.1--3.1)   0.014
  Comorbidity                                                                                                                             
          Diabetes                  36 (23.5)             112 (18.8)            0.186                   NA                                
          Cardiovascular disease    81 (52.9)             254 (42.5)            0.021                   1.2 (0.8--1.8)   0.479            
          Pulmonary disease         18 (11.8)             62 (10.4)             0.622                   NA                                
          Kidney disease            5 (3.3)               7 (1.2)               0.065                   NA                                
          Liver disease             4 (2.6)               19 (3.2)              0.716                   NA                                
          Cerebrovascular disease   43 (28.1)             89 (14.9)             \<0.001                 1.7 (1.1--2.8)   0.026            
  Emergency                         (+)                   7 (5.6)               24 (5.2)                0.850            NA               
  T4 tumor                          (+)                   27 (17.6)             143 (24)                0.096            NA               
  National health insurance         Medical care          22 (14.4)             59 (9.9)                0.110            NA               
  Region                            Rural (*vs*. urban)   35 (22.9)             167 (28)                0.205            NA               
  Preoperative CRT                  (+)                   7 (4.6)               68 (11.4)               0.012            0.5 (0.2--1.2)   0.105
  Location                          Colon                 87 (56.9)             324 (54.3)              0.566            NA               
                                    Rectum                66 (43.1)             273 (45.7)                                                
  Surgical approach                 Open                  70 (45.8)             243 (40.7)              0.259            NA               
                                    Minimally invasive    83 (54.2)             354 (59.3)                                                
  Name of operation                 APR, Hartmann         24 (15.7)             62 (10.4)               0.445            NA               
                                    LAR                   44 (28.8)             217 (36.3)                                                
                                    PC                    1 (0.7)               5 (0.8)                                                   
                                    AR, LHC               42 (27.5)             154 (25.8)                                                
                                    TC, STC               4 (2.6)               10 (1.7)                                                  
                                    RHC                   37 (24.2)             144 (24.1)                                                
                                    Other                 1 (0.7)               5 (0.8)                                                   
  TNM                               II                    83 (54.2)             235 (39.4)              0.001            2.0 (1.4--3.1)   0.001
                                    III                   70 (45.8)             362 (60.6)                               1                
  Metastatic lymph node (number)    1--3                  43 (61.4)             235 (64.9)              0.577            NA               
  ≤4                                27 (38.6)             127 (35.1)                                                                      
  CRM                               ≤1 mm                 10 (15.2)             50 (18.3)               0.546            NA               
  Histologic grade                  G3, G4                8 (5.2)               51 (8.5)                0.174            NA               
  30-day complications              (+)                   73 (47.7)             170 (28.5)              \<0.001          2.2 (1.5--3.3)   \<0.001
  Anastomotic leakage               (+)                   11 (7.2)              24 (4)                  0.097            NA               
  Clavien-Dindo grade               3, 4, 5               39 (25.5)             72 (12.1)               \<0.001          NA               
  ICU admission                     (+)                   82 (53.6)             148 (24.8)              \<0.001          2.4 (1.6--3.7)   \<0.001
  Transfusion                       (+)                   62 (40.5)             178 (29.8)              0.011            1.1 (0.7--1.8)   0.563
  Operative time                    ≥300 min              9 (7.3)               52 (11.3)               0.191            NA               
  Open conversion                   (+)                   11 (13.3)             35 (9.9)                0.368            NA               

BMI, body mass index; ASA, American Society of Anesthesiologists; CRT, chemoradiation; APR, abdominoperineal resection; LAR, low anterior resection; PC, proctocolectomy; AR, anterior resection; LHC, left hemicolectomy; TC, total colectomy; STC, subtotal colectomy; RHC, right hemicolectomy; TNM, tumor-node-metastasis; CRM, circumferential resection margin; ICU, intensive care unit; HR, hazard ratio; CI, confidence interval; NA, not applied

Factors associated with adjuvant chemotherapy delay {#sec016}
---------------------------------------------------

Based on multivariate analysis, factors affecting chemotherapy delay ≥8 weeks were male sex (HR = 4.2), rectal primary cancer (HR = 5.4), and the presence of postoperative complications (HR = 2.5). The use of preoperative chemoradiation treatment for rectal cancer did not influence adjuvant chemotherapy delay. Rates of adjuvant chemotherapy were 19.4% in patients with 8 or more weeks and 11% in patients who received treatment in less than 8 weeks (**[Table 3](#pone.0138720.t003){ref-type="table"}**).

10.1371/journal.pone.0138720.t003

###### Factors associated with a ≥8-week delay to adjuvant chemotherapy (n = 597).

![](pone.0138720.t003){#pone.0138720.t003g}

                                                          Univariate   Multivariate                               
  --------------------------------- --------------------- ------------ -------------- --------- ----------------- -------
  Age (years)                       \<80                  29 (93.5)    520 (91.9)     0.738     NA                
                                    ≥80                   2 (6.5)      46 (8.1)                                   
  Age subgroups                     ≤70                   19 (5.3)     337 (94.7)               NA                
                                    71--75                9 (6.5)      129 (93.5)                                 
                                    76--80                2 (2.9)      68 (97.1)                                  
                                    81--85                1 (3.8)      25 (96.2)                                  
                                    ≥86                   0 (0)        7 (100)                                    
  Sex                               Female                3 (9.7)      212 (37.5)     0.002     1                 0.022
                                    Male                  28 (90.3)    354 (62.5)               4.2 (1.2--14.2)   
  BMI                               ≥30 kg/m^2^           0 (0)        18 (3.2)       0.313     NA                
  ASA score                         3,4                   5 (16.1)     76 (13.4)      0.669     NA                
  Comorbidity                                                                                                     
          Diabetes                  6 (19.4)              106 (18.7)   0.931          NA                          
          Cardiovascular disease    12 (38.7)             242 (42.8)   0.657          NA                          
          Pulmonary disease         5 (16.1)              57 (10.1)    0.282          NA                          
          Kidney disease            0 (0)                 7 (1.2)      0.533          NA                          
          Liver disease             2 (6.5)               17 (3)       0.287          NA                          
          Cerebrovascular disease   8 (25.8)              81 (14.3)    0.08           NA                          
  Emergency                         (+)                   1 (4.5)      23 (5.3)       0.885     NA                
  T4 tumor                          (+)                   11 (35.5)    132 (23.3)     0.122     NA                
  National health insurance         Medical care          4 (12.9)     55 (9.7)       0.563     NA                
  Region                            Rural (*vs*. urban)   10 (32.3)    157 (27.7)     0.585     NA                
  Preoperative CRT                  (+)                   6 (19.4)     62 (11)        0.152     NA                
  Location                          Colon                 5 (16.1)     319 (56.4)     \<0.001   1                 0.001
                                    Rectum                26 (83.9)    247 (43.6)               5.4(2--14.5)      
  Surgical approach                 Open                  17 (54.8)    226 (39.9)     0.1       NA                
                                    Minimally invasive    14 (45.2)    340 (60.1)                                 
  Name of operation                 APR, Hartmann         5 (16.1)     57 (10.1)      0.001     NA                
                                    LAR                   22 (71)      195 (34.5)                                 
                                    PC                    0 (0)        5 (0.9)                                    
                                    AR, LHC               2 (6.5)      152 (26.9)                                 
                                    TC, STC               0 (0)        10 (1.8)                                   
                                    RHC                   2 (6.5)      142 (25.1)                                 
                                    Other                 0 (0)        5 (0.9)                                    
  TNM                               II                    14 (45.2)    221 (39)       0.497     NA                
                                    III                   17 (54.8)    345 (61)                                   
  Metastatic lymph node (number)    1--3                  10 (65.2)    225 (58.8)     0.590     NA                
                                    ≤4                    7 (34.8)     120 (41.2)                                 
  CRM                               ≤1 mm                 5 (19.2)     45 (18.2)      0.899     NA                
  Histologic grade                  G3, G4                0 (0)        51 (9)         0.081     NA                
  30-day complications              (+)                   18 (58.1)    152 (26.9)     \<0.001   2.5 (1.1--5.4)    0.021
  Anastomotic leakage               (+)                   8 (25.8)     16 (2.8)       \<0.001   NA                
  Clavien-Dindo grade               3, 4, 5               12 (38.7)    60 (10.6)      \<0.001   NA                
  ICU admission                     (+)                   8 (25.8)     140 (24.7)     0.893     NA                
  Transfusion                       (+)                   15 (48.4)    163 (28.8)     0.02      2 (0.9--4.3)      0.077
  Operative time                    ≥300 min              3 (13.6)     49 (11.2)      0.723     NA                
  Open conversion                   (+)                   5 (35.7)     30 (8.8)       0.001     NA                

BMI, body mass index; ASA, American Society of Anesthesiologists; CRT, chemoradiation; APR, abdominoperineal resection; LAR, low anterior resection; PC, proctocolectomy; AR, anterior resection; LHC, left hemicolectomy; TC, total colectomy; STC, subtotal colectomy; RHC, right hemicolectomy; TNM, tumor-node-metastasis; CRM, circumferential resection margin; ICU, intensive care unit; HR, hazard ratio; CI, confidence interval; NA, not applied

Oncologic outcomes by use and delay of adjuvant chemotherapy {#sec017}
------------------------------------------------------------

The 5-year overall survival rate was 39.4% in the no-chemotherapy group, 56.5% in the ≥8-week group and 80.1% in \<8-week group (p\<0.001) (**[Fig 1](#pone.0138720.g001){ref-type="fig"}**). The 5-year recurrence-free survival rate was 44.8% in the no-chemotherapy group, 39.6% in the ≥8-week delay group and 71.2% in the \<8-week group (p\<0.001) (**[Fig 2](#pone.0138720.g002){ref-type="fig"}**).

![Overall survival according to use of adjuvant chemotherapy use.\
Five-year rates by group: 39.4% no chemotherapy; 56.5% delay ≥8 weeks; 80.1% \<8 weeks (p\<0.001).](pone.0138720.g001){#pone.0138720.g001}

![Recurrence-free survival according to use of adjuvant chemotherapy use.\
Five-year rates by group: 44.8% no chemotherapy; 39.6% delay ≥8 weeks; 71.2% \<8 weeks (p\<0.001).](pone.0138720.g002){#pone.0138720.g002}

Prognostic survival factors by Cox proportional hazard modeling {#sec018}
---------------------------------------------------------------

Independent prognostic factors for overall survival included TNM III stage (HR = 2.04), chemotherapy use (after ≥8 week: HR = 0.39 and within \<8 weeks: HR = 0.22). Independent prognostic factors for recurrence-free survival were TNM III stage (HR = 2.26) and chemotherapy use (within \<8 weeks, HR = 0.35) (**[Table 4](#pone.0138720.t004){ref-type="table"}**).

10.1371/journal.pone.0138720.t004

###### Prognostic factors for survival on Cox proportional hazard modeling.

![](pone.0138720.t004){#pone.0138720.t004g}

                                    Overall survival    Recurrence-free survival                       
  --------------------------------- ------------------- -------------------------- ------------------- ---------
  Use of and time to chemotherapy                                                                      
           (No use)                 Reference                                      Reference           
           (≥8 weeks)               0.39 (0.2--0.78)    0.008                      0.73 (0.4--1.33)    0.301
           (\<8 weeks)              0.22 (0.15--0.32)   \<0.001                    0.35 (0.24--0.5)    \<0.001
  TNM (III *vs*. II)                2.04 (1.44--2.9)    \<0.001                    2.26 (1.65--3.09)   \<0.001
  Age (≥80 *vs*. \<80 years)        1.38 (0.9--2.12)    0.142                      0.97 (0.64--1.48)   0.896
  30-day complications (+ *vs*.-)   1.29 (0.92--1.79)   0.139                      1.18 (0.87--1.59)   0.280
  ASA score (3,4 *vs*. 1,2)         1.24 (0.83--1.85)   0.287                      1.11 (0.76--1.61)   0.605

HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis; ASA, American Society of Anesthesiologists

Discussion {#sec019}
==========

The major findings of this study were that different factors affected lack of chemotherapy (older age, ASA score, underlying cerebrovascular disease, stage II disease, postoperative complications, and ICU admission) and delay of chemotherapy (male, rectal cancer, and postoperative complications), with the exception of postoperative complications. Both lack of chemotherapy and delay ≥8 weeks negatively influenced overall and recurrence-free survival. Timely initiation of chemotherapy (\<8 weeks) was a favorable prognostic factor for overall and recurrence-free survival.

Factors associated with the use of adjuvant chemotherapy {#sec020}
--------------------------------------------------------

Various factors were associated with the use of adjuvant chemotherapy. Older patients receive adjuvant chemotherapy less often than younger patients \[[@pone.0138720.ref012], [@pone.0138720.ref013]\]. Dobie *et al*.\[[@pone.0138720.ref014]\] found that the rate of adjuvant chemotherapy decreased with advanced age; in their study, 78.9% of patients in the 66- to 70-year-old group received chemotherapy compared to 71.2% in the 71- to 75-year-old group, 56.3% in the 76- to 80-year-old group, 29.8% in the 81- to 85-year-old group and 8.1% in the 86-year-or-older group. We observed the same pattern of decline in chemotherapy use with increasing age.

Patient comorbidity is also related to chemotherapy use. Most studies that measure this outcome use the Charlson comorbidity index, with a higher index score associated with a lower rate of chemotherapy use \[[@pone.0138720.ref013], [@pone.0138720.ref015]\]. Gross *et al*.\[[@pone.0138720.ref016]\] demonstrated that chronic illnesses such as congestive heart failure, chronic obstructive pulmonary disease, and diabetes influence decreased use of adjuvant chemotherapy. In this study, underlying cerebrovascular disease was a negative predictor for chemotherapy use.

Patient functional status is another important factor when considering chemotherapy use. Age, comorbidity, and functional status are closely related to preoperative health status. Although data are scarce on functional status and use of chemotherapy in an adjuvant setting, patients with stage IV disease and diminished performance status are less likely to receive palliative chemotherapy \[[@pone.0138720.ref017]\]. As a measure of functional status, we used ASA score, which is a widely adopted grading system for predicting postoperative morbidity and mortality. We observed that ASA scores of 3 and 4 were independent negative predictors for use of chemotherapy.

Tumor histopathology is related to chemotherapy use. Greater numbers of metastatic lymph nodes are associated with more frequent use of chemotherapy\[[@pone.0138720.ref013]\], likely due to increased consultation needs\[[@pone.0138720.ref018]\]. Surgical and medical oncologists tend to be more active in recommending chemotherapy in patients with higher-risk tumors. In our study, the number of metastatic nodes was not related to use of chemotherapy, but stage III disease was associated with more frequent use of chemotherapy compared to stage II.

Postoperative complications result in prolonged patient recovery, longer hospital stays, and a higher likelihood of readmission \[[@pone.0138720.ref019], [@pone.0138720.ref020]\]. Accordingly, the presence of postoperative complications is associated with less frequent use of chemotherapy, \[[@pone.0138720.ref021]\] as was confirmed in this study.

Hospital or physician factors may also affect chemotherapy use. This study was performed in a single tertiary referral center, which allowed good control of systemic factors. In our hospital, adjuvant treatment plans were based on final pathology reports and decided after surgery in weekly meetings of multidisciplinary teams. The treating oncologists explained the overall adjuvant treatment plan and estimated the prognosis of the patient. Patients and family then chose whether or not to receive adjuvant chemotherapy and some refused further treatment. We were unable to evaluate the frequency of patient refusal. In addition, socioeconomic status and race/ethnicity, marital status, area of residence, and income influence the use of chemotherapy \[[@pone.0138720.ref005], [@pone.0138720.ref012], [@pone.0138720.ref022], [@pone.0138720.ref023]\].

Factors associated with delay of adjuvant chemotherapy {#sec021}
------------------------------------------------------

Older age, black race, prolonged postoperative recovery, severe comorbidity, advanced histologic grade, and unmarried status are associated with delay of adjuvant chemotherapy \[[@pone.0138720.ref019], [@pone.0138720.ref022], [@pone.0138720.ref024]\]. In this study, presence of postoperative complications was an independent predictor for chemotherapy delay. In the delayed-chemotherapy group, 90.3% were men (*vs*. 62.5% in the nondelayed group), 83.9% had rectal cancer (*vs*. 43.6% in the nondelayed group), 58.1% experienced postoperative complications (*vs*. 26.9% in the nondelayed group) and 25.8% had anastomotic leakage (*vs*. 2.8% in the nondelayed group). These factors appeared to be related to surgical outcomes. Male sex is a well-known risk factor for anastomotic leakage after rectal cancer surgery \[[@pone.0138720.ref025]\]. Thus, surgeons should be aware of the detrimental effect of postoperative complications on time to chemotherapy initiation.

Institutional delay between interdepartmental consultations has been suggested as another factor related to chemotherapy delay \[[@pone.0138720.ref006]\]. In this study, all included patients underwent surgery in our hospital and were discussed at multidisciplinary team meetings. Accordingly, the effect of institutional delay was likely to be small.

Oncologic outcomes related to use and delay of chemotherapy {#sec022}
-----------------------------------------------------------

Adjuvant chemotherapy improves overall and recurrence-free rates of survival in stage II and III colorectal cancer\[[@pone.0138720.ref012]\]. One meta-analysis showed that more than 8 weeks of delay to adjuvant chemotherapy in stage III colorectal cancer worsened overall survival \[[@pone.0138720.ref022]\]. However, Zeig-Owens *et al*.\[[@pone.0138720.ref023]\] demonstrated that a chemotherapy delay of more than 45 days was not associated with survival of patients with stage II and III colon cancer. Additional controversies are over the definition of delay, which has been defined as 45 days\[[@pone.0138720.ref023], [@pone.0138720.ref026]\], 8 weeks\[[@pone.0138720.ref027]--[@pone.0138720.ref029]\], and 3 months\[[@pone.0138720.ref019]\] in various studies. In this study, delay of chemotherapy ≥8 weeks showed oncologic benefits in terms of overall survival when compared to no chemotherapy, but no benefits in recurrence-free survival. Timely initiation of chemotherapy in \<8 weeks was a favorable prognostic factor for overall and recurrence-free survival. Postoperative complications are suggested to be risk factors for inferior oncologic outcomes\[[@pone.0138720.ref030]\]. In this study, surgical complications were associated with lack of and delay of chemotherapy, but were not a prognostic factor. This study used 8 weeks as the cutoff for chemotherapy delay. This decision was based on Health Insurance Review Assessment Service of South Korea claims data on time to chemotherapy initiation in patients with colorectal cancer. In Korea, if patients do not receive adjuvant chemotherapy or undergo chemotherapy after more than 8 weeks, treating physicians must notify a government agency.

This study was limited by its single-center, retrospective design. In addition, data regarding chemotherapy dose reduction or discontinuation were not available. Although all medical records were reviewed, we acknowledge that some treatment-related events such as ICU admission or transfusion could have been missed.

In summary, we identified factors associated with not receiving chemotherapy or experiencing a ≥8-week delay to chemotherapy in an adjuvant setting after surgery for stage II or III colorectal cancer. Among the factors investigated, the presence of postoperative complications correlated with both not receiving and delay of chemotherapy. Timely initiation of chemotherapy (\<8 weeks postoperative) was a favorable prognostic factor for overall and recurrence-free survival. To increase the proportion of patients receiving chemotherapy and timely initiation of chemotherapy, surgical complications should be minimized after curative resection.
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